EUVIMEDEUVIMED entdecken
Crossref

Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing statin treatment

Rikuo Sakai, Teruo Sekimoto, Shinji Koba, Hiroyoshi Mori, Naoki Matsukawa, Taito Arai, Yuya Yokota, Shunya Sato, Hideaki Tanaka, Ryota Masaki, Yosuke Oishi, Kunihiro Ogura und 8 weitere

Journal of Clinical Lipidology · 2023

DOI: 10.1016/j.jacl.2023.01.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2023. Verfasst von Rikuo Sakai und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Drug-Eluting Stents, Percutaneous Coronary Intervention, Atherosclerosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neoatherosclerosis (NA), which refers to neointimal atherosclerosis within a stent, is considered one of the underlying causes of late-phase stent failure following a newer generation drug-eluting stent (DES) placement procedure. Even contemporary guideline-directed medical therapy may be insufficient to prevent NA. OBJECTIVE: This study aimed to investigate how intricately lipid markers are associated with NA formation in the early phase of treatment with well-maintained low-density lipoprotein cholesterol (LDL-C) levels. METHODS: We enrolled 114 consecutive patients undergoing statin treatment and percutaneous coronary intervention (PCI) with current-generation DES for coronary artery disease. At a median 12 months after PCI, optical coherence tomography (OCT) was performed. Various lipid markers, including LDL-C, triglyceride (TG), triglyceride-rich lipoprotein cholesterol (TRL-C), non-high-density lipoprotein cholesterol (non-HDL-C), malondialdehyde-modified LDL (MDA-LDL), and several apolipoproteins, were also evaluated. RESULTS: NA was observed in 17 (14.9%) patients. The LDL-C level was equivalent in patients with or without NA (77.2 vs. 69.8 mg/dL; p=0.15). However, the levels of TG, apolipoprotein C3 (apoC3), TRL-C, non-HDL-C, and apolipoprotein B (apoB), and MDA-LDL were significantly higher in the patients with NA. Furthermore, multivariate logistic regression adjusting for HbA1c and stent duration revealed apoC3, TRL-C, non-HDL-C, apoB, and MDA-LDL levels as risk factors for NA. However, when apoB was included as a covariate, other factors became nonsignificant. CONCLUSIONS: Abnormal triglyceride-rich lipoprotein metabolism and high atherogenic apoB-containing lipoprotein particle numbers are associated with the formation of NA in patients undergoing statin treatment at a median 12 months post-PCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsDrug-Eluting StentsPercutaneous Coronary InterventionAtherosclerosisHumansCholesterol, LDLLipoproteinsTriglyceridesStentsApolipoproteins BCholesterol, HDL

Stichwörter der Autor:innen

Apolipoptotein BApolipoptotein C3NeoatherosclerosisNon-high-density lipoprotein cholesterolOptical coherence tomographyTriglyceride-rich lipoprotein cholesterol

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLLipoproteinsTriglyceridesApolipoproteins BCholesterol, HDL

Autor:innen und Institutionen

  • Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan.
  • Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan. Electronic address: sekimoto.cardiology@gmail.com.
  • Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan; Department of Perioperative Medicine, Division of General Medicine, Showa University School of Dentistry, Tokyo, Japan.
  • Department of Medicine, Division of Cardiology, Showa University Fujigaoka Hospital, Kanagawa, Japan.
  • Department of Legal Medicine, Showa University School of Medicine, Tokyo, Japan.

Zitieren

APA

Sakai, R., Sekimoto, T., Koba, S., Mori, H., Matsukawa, N., Arai, T., Yokota, Y., Sato, S., Tanaka, H., Masaki, R., Oishi, Y., Ogura, K., Arai, K., Nomura, K., Sakai, K., Tsujita, H., Kondo, S., Tsukamoto, S., Suzuki, H., & Shinke, T. (2023). Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing statin treatment. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2023.01.004

Vancouver

Sakai R, Sekimoto T, Koba S, Mori H, Matsukawa N, Arai T, et al. Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing statin treatment. Journal of Clinical Lipidology. 2023. doi:10.1016/j.jacl.2023.01.004

BibTeX
@article{Sakai2023,
  author = {Sakai, Rikuo and Sekimoto, Teruo and Koba, Shinji and Mori, Hiroyoshi and Matsukawa, Naoki and Arai, Taito and Yokota, Yuya and Sato, Shunya and Tanaka, Hideaki and Masaki, Ryota and Oishi, Yosuke and Ogura, Kunihiro and Arai, Ken and Nomura, Kosuke and Sakai, Koshiro and Tsujita, Hiroaki and Kondo, Seita and Tsukamoto, Shigeto and Suzuki, Hiroshi and Shinke, Toshiro},
  title = {Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing statin treatment},
  journal = {Journal of Clinical Lipidology},
  year = {2023},
  doi = {10.1016/j.jacl.2023.01.004}
}
Kostenlos starten →